Andere Sprachen Legend Biotech Corporation

Aktien

A2P5AH

US52490G1022

LEGN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 13.05.2024			% 5 Tage	% 1. Jan.
42,97 ^USD	-0,62 %		-5,06 %	-28,59 %

15:32	Sektor-Update: Aktien des Gesundheitswesens geben vor dem Glockenschlag am Montag nach	MT
15:11	Sektor Update: Gesundheitswesen	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Sector Update: Health Care Stocks Decline Pre-Bell Monday	15:32
Sector Update: Health Care	15:11
Legend Biotech Q1 Net Loss Narrows as Revenue Rises; Shares Rise Pre-Bell	13:49
Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales	13:37
Stock Futures Rise Pre-Bell Ahead of Key Inflation Data; Asia, Europe Churn	13:36
Legend Biotech : LEGN Q1 2024 Earnings Presentation	13:13
Earnings Flash (LEGN) LEGEND BIOTECH CORPORATION Reports Q1 Revenue $94M	13:08
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights	13:04
Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission	23.04.
Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer	22.04.
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma	22.04.
Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma	22.04.
US FDA mandates label updates on CAR-T cancer therapies	19.04.
Genscript Biotech's Unit Logs $157 Million in Q1 Sales of Blood Cancer Drug	17.04.
Legend Biotech : Announces Preliminary Sales for CARVYKTI® for the Quarter Ended March 31, 2024 - Form 6-K	16.04.
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results	11.04.
Genscript Biotech Unit's Refractory Multiple Myeloma Drug Gets FDA Approval	09.04.
Innovative personalised immunotherapy approved for multiple myeloma	08.04.
Sector Update: Health Care Stocks Flat to Higher Premarket Monday	08.04.
Johnson & Johnson, Legend Biotech's Carvykti Receives FDA Approval to Treat Relapsed, Refractory Multiple Myeloma	08.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Legend Biotech Corporation

Aktien

A2P5AH

US52490G1022

LEGN

Andere Sprachen

Filter